Merck Research Laboratories CMO Roy Baynes
Merck's Keytruda uncorks full data on latest adjuvant win — this time in melanoma — adding bricks to early cancer wall
In recent months, the battle for PD-(L)1 dominance has spilled over into early cancer with Merck’s Keytruda and Bristol Myers Squibb’s Opdivo all alone on …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
